GMG President Della Schmidt said she first heard about the CEO program when she attended a conference in Sioux Falls, South Dakota, and knew she wanted to bring it to Mankato and surrounding ...

Among 12 abstracts shared, the company highlighted pivotal Phase 3 study findings and real-world data underscoring the treatment’s promise and the ongoing unmet needs in gMG care. Key findings ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 ...

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete with rivals in ...

Rystiggo (rozanolixizumab) has been given the green light by the FDA for both anti-AChR and anti-MuSK antibody-positive gMG based on the results of the MycarinG study, which showed that treatment ...

With the highest MG-ADL response rate among all drugs for gMG with phase 3 studies reported to date, Telitacicept will provide an important new treatment option gMG. Telitacicept is a novel ...

Inebilizumab showed significant efficacy in improving MG-ADL and QMG scores in gMG patients compared to placebo over 26 weeks. The trial included 238 patients, with 80% AChR+ and 20% MuSK+ ...

In addition, human factors validation studies demonstrated that participants with gMG or CIDP, or their caregivers, safely and successfully prepared and administered Vyvgart Hytrulo with the prefilled ...